September 20, 2014 4:42 PM ET

Biotechnology

Company Overview of GlobeImmune Inc.

Company Overview

GlobeImmune Inc. operates as a biopharmaceutical company. The company develops and manufactures Tarmogens, a molecular immunotherapy vaccine for the treatment of cancer and infectious diseases. Its products include GI-4000 for pancreas, non-small cell lung, colorectal, endometrial, and ovarian cancers, as well as melanoma and multiple myeloma; GI-6207 for the treatment of human epithelial cancers, including non-small cell lung cancer, colorectal, pancreas, breast, gastric, and medullary thyroid cancers; GI-6301, a Tarmogen used for the treatment of lung, breast, colon, bladder, kidney, ovary, uterus, and prostate cancers; and GS-4774 a therapeutic vaccine for chronic HBV infection. GlobeImmu...

1450 Infinite Drive

Louisville, CO 80027

United States

Founded in 1995

24 Employees

Phone:

303-625-2700

Fax:

303-625-2710

Key Executives for GlobeImmune Inc.

Chief Executive Officer
Age: 63
Total Annual Compensation: $388.1K
Principal Financial & Accounting Officer
Age: 49
Total Annual Compensation: $191.5K
Vice President of Corporate Development
Age: 45
Total Annual Compensation: $188.8K
Compensation as of Fiscal Year 2013.

GlobeImmune Inc. Key Developments

GlobeImmune Inc. Presents at Aegis Capital 2014 Healthcare & Technology Conference, Sep-12-2014 09:30 AM

GlobeImmune Inc. Presents at Aegis Capital 2014 Healthcare & Technology Conference, Sep-12-2014 09:30 AM. Venue: The Encore at Wynn Las Vegas, 3121 Las Vegas Blvd. South, Las Vegas, NV 89109, United States. Speakers: Timothy C. Rodell, Chief Executive Officer, President and Director.

GlobeImmune Inc. Announces Financial Results for the Second Quarter and Six Months Ended June 30, 2014

GlobeImmune Inc. announced financial results for the second quarter and six months ended June 30, 2014. The net loss for the second quarter was $5.7 million, bringing the net loss for the year to $8.2 million. For the six months ended June 30, 2014, the company reported a net loss of $8.2 million compared to a net loss of $0.5 million for the comparable period in the six months ended June 30, 2013.

GlobeImmune, Inc.(NasdaqCM:GBIM) added to NASDAQ Composite Index

GlobeImmune, Inc. will be added to the NASDAQ Composite Index.

Similar Private Companies By Industry

Company Name Region
Propagenix Inc. United States
Arcxis Biotechnologies, Inc. United States
Cylene Pharmaceuticals, Inc. United States
Plexigen, Inc. United States
Kellbenx Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
January 31, 2014
--
Private Placement
November 12, 2013
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GlobeImmune Inc., please visit www.globeimmune.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.